%0 Journal Article
%A Knauf, Wolfgang
%A Dingeldein, Gerrit
%A Schlag, Rudolf
%A Welslau, Manfred
%A Moehler, Thomas
%A Terzer, Tobias
%A Walter, Sarah
%A Goldschmidt, Hartmut
%A Raab, Marc-Steffen
%A group, BPV trial
%T First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
%J European journal of haematology
%V 105
%N 2
%@ 1600-0609
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2020-00525
%P 116-125
%D 2020
%Z 2020 Aug;105(2):116-125
%X The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the 3-drug-combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM).Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of 9 cycles.46 patients were included into the trial with a median age of 76 years. 19 patients had renal impairment at baseline. The ORR was 76.5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32155662
%R 10.1111/ejh.13409
%U https://inrepo02.dkfz.de/record/153915